Clinical trial for treatment of dry eye disease clears Phase 2 hurdle
Aldeyra Therapeutics announced today that it has achieved the primary endpoint of ocular redness in its randomly assigned, double-masked, vehicle-controlled Phase 2 clinical trial in dry eye disease.
